-Member Login

Forgot your password?

Job Postings

Loading...

Let's Stay Connected

Find us on the popular social networks

Facebook Twitter LinkedIn Youtube

Experimental Biology Program 2012

Click here for a PDF file of the full EB 2012 program (6.56 MB).

Saturday, April 21, 2012 - Wednesday, April 25, 2012  
San Diego, CA

For the past 3 years ASPET members attending EB have spent a day volunteering in the local communities: 2009 building homes with Habitat for Humanity in the Upper 9th Ward in New Orleans; 2010 and 2011 preparing and serving meals to homeless residents of Pasadena and Washington DC, respectively.  The Behavioral Pharmacology Division of ASPET will again sponsor a volunteer opportunity at EB 2012 in San Diego.  Negotiations are underway with several local agencies for volunteer activities on Friday April 20, 2012. The details of those activities will develop over the next month or two as it becomes clear how many ASPET attendees will participate.  If you plan to volunteer please contact Charles P France at france@uthscsa.edu, 210 567 6969 (voice), or 210 567 0104 (fax) at your earliest convenience.
  

Saturday, April 21, 2012

Diversity Committee Workshop: Building a research career in pharmacology: a focus on health disparities
San Diego Convention Center, Room 2
12:00 pm – 2:30 pm
Chairs: M. I. Davila-Garcia, Howard Univ. Col. of Med.

     Science and disparities: Meeting the challenge of the 21st century.
     Robert G. Robinson, Consultant

     Lipotoxicity, type 2 diabetes and health disparities.
     Marino De Leon, Loma Linda Univ. Sch. of Med.

     Cancer drug discovery and health disparities.
     Eileen J. Kennedy, Univ. of Georgia, Col. of Pharmacy

     Drug-plant interaction in the American Indian/Alaskan Native populations; no control of potential harm.
     Joseph Yracheta, Univ. of Washington Sch. of Pharm.

     Drug abuse research; from molecular studies to differential treatment.
     M. I. Davila-Garcia, Howard Univ. Col. of Med.

Graduate Student Colloquium
: Communication
San Diego Convention Center, Room 2
2:45 pm – 5:15 pm
Chairs: Lisa Schrott, Louisiana State Univ. Hlth. Sci. Ctr., Jeff Fedan, NIOSH, and Michael J. Seminerio, West Virginia Univ.

     Keynote: Get that job! How to ace your interview
        Negotiating Session: Negotiating your job offer: A hands-on exercise

     Beth A. Fischer, Survival Skills & Ethics Program, Univ. of Pittsburgh

2012 Teaching Institute: The use of social media in pharmacology education
San Diego Convention Center, Room 3
12:00 pm – 2:30 pm
Chair: Lynn Crespo, Greenville Hosp. System

    Texts, tweets and blogs:  Common practices
       
William B. Jeffries, Univ. of Vermont Col. of Med.

    Wikis and Wikipedia as teaching tools
     Jill Jemison, Univ. of Vermont Col. of Med.

     Editing and publishing on Wikipedia
     Lynn M. Crespo, Univ. of South Carolina Sch. of Med., Greenville

ASPET Business Meeting
San Diego Convention Center, Ballroom 20D
6:00 pm – 7:30 pm

ASPET Opening and Awards Reception
San Diego Convention Center, Center Terrace
7:30 pm – 9:30 pm

Back to top

 

Sunday, April 22, 2012

Diversity Mentoring Breakfast
San Diego Marriott Marquis & Marina, Anaheim Room
7:30 am – 9:00 am

Building a pharmacology course from scratch:  Benefits and pitfalls of a cut and paste pharmacology course
San Diego Marriott Marquis & Marina, Marriott Hall Salon 5
9:30 am – 12:00 pm
Sponsored by the Division for Pharmacology Education
Chair: John Szarek, Commonwealth Med. Col.

     Coordinating development of a pharmacology course using materials from volunteer faculty across North America.
     Leszek Wojnowski, Johannes Gutenberg-Univ. Mainz, Germany

     Preparing materials for use at sites other than your own medical school.
    
Peter G. Anderson, Univ. of Alabama at Birmingham

     Facilitating learning anywhere, anytime using mobile devices.
     John Bartlett, Duke Univ. Med. Ctr.

     Does it work? Student and faculty perspectives.
     John Szarek, Commonwealth Med. Col.

     Panel discussion: Should we develop a national repository of pharmacology topics?
    

Emerging concepts in G protein dependent PLC regulation and physiology
San Diego Convention Center, Room 2
9:30 am – 12:00 pm
Sponsored by the Division for Molecular Pharmacology
Chair: Alan V. Smrcka, Univ. of Rochester Sch. of Med.

     Kinetic scaffolding mediated by a phospholipase C-beta and Gq signaling complex.
     T. Kendall Harden, Univ. of North Carolina

     Synergystic regulation of phospholipase C beta isoforms as a  coincidence detector for GPCR activation.
     Elliot Ross, Univ. of Texas Southwestern Med. Ctr.

     Role for PLCbeta1b in Gq driven cardiac hypertrophy.
     Elizabeth Woodcock, Baker Medical Research Inst.

     PLCe as a localized signal integrator downstream of GPCRs  and RTKs.
     Alan V. Smrcka, Univ. of Rochester Sch. of Med.

     Signaling mechanisms for neutrophil chemotaxis regulation.
     Dianquing Wu, Yale Univ.

Pharmacology and therapeutic potential of histamine H3 and H4 receptor ligands
San Diego Convention Center, Room 3
9:30 am – 12:00 pm
Sponsored by the Divisions for Drug Discovery, Development & Regulatory Affairs; Molecular Pharmacology; Neuropharmacology; Behavioral Pharmacology; and Integrative Systems, Translational & Clinical Pharmacology
Chair: Robin L. Thurmond, Johnson & Johnson Pharmaceut. Res. & Develop., L.L.C.

     Pharmacology of histamine receptors.
     Rob Leurs, Vrije Univ. Fac. Of Sci., Amsterdam

     Therapeutic potential of histamine H3 receptor ligands.
     Jean-Charles Schwartz, Bioprojet Biotech, France

     Molecular and cell biology of the histamine H4 receptor.
     Thomas Werfel, Hannover Med. Sch., Germany

     Novel antihistamines that target the histamine H4 receptor.
     Robin L. Thurmond, Johnson & Johnson Pharmaceut. Res. & Develop., L.L.C.

     Efficacy of a histamine H3 receptor antagonist (JNJ-39220675) and pseudoephedrine versus placebo in the prophylactic treatment of seasonal allergic rhinitis in an EEC model: randomized, three-way cross-over
     study

     William T. Barchuk, Janssen R&D

Neuropsychological correlates of stimulant treatment for ADHD in adolescents and adults
San Diego Convention Center, Room 4
9:30 am – 12:00 pm
Sponsored by the Divisions for Behavioral Pharmacology and Neuropharmacology
Chair: Claire Advokat, Louisiana State Univ.

     What do we know about the cognitive effects of stimulant drugs in adults?
     Claire Advokat, Louisiana State Univ.

     Chronic methylphenidate treatment in adolescent monkeys: effects on brain dopamine systems and drug reinforcement.
     Linda J. Porrino, Wake Forest Univ. Sch. of Med.

     Treatment outcome in Attention-Deficit/Hyperactivity Disorder, with medication, behavioral treatment, and their combination.
     William E. Pelham, Jr., Florida Intl. Univ.

     Interventions for cognitive control impairments in ADHD: developmental considerations
     Julie Schweitzer, Univ. of California, Davis

     Acute tolerance to methylphenidate: Age-related differences in children, adolescents, and adults. 
     James M. Swanson, Univ. of California, Irvine Sch. of Med

Role of pharmacogenetics in oncology
San Diego Convention Center, Room 5A
9:30 am – 12:00 pm
Sponsored by the Divisions for Toxicology; Drug Metabolism; and Integrative Systems, Translational & Clinical Pharmacology
Chairs: E. Penni Black, Univ. of Kentucky and Hollie Swanson, Univ. of Kentucky Col. of Med.

     Utilizing gene expression signatures to predict response to targeted therapies in lung and colorectal cancer.
     E. Penni Black, Univ. of Kentucky

     A personalized medicine case study in NSCLC: Crizotinib story.
     Hakan Sakul, Pfizer

     Activation of AMP-dependent kinase and treatment of lung cancers.
     Richard Moran, Virginia Comm. Univ.

     Discussion

Multi-target agents: The yin and yang of rational drug discovery
San Diego Convention Center, Room 5B
9:30 am – 12:00 pm
Sponsored by the Divisions for Neuropharmacology; Toxicology; Molecular Pharmacology; and Drug Discovery, Development & Regulatory Affairs
Chairs: Alan J. Cross, AstraZeneca and Michael W. Wood, AstraZeneca

     Introduction
     Alan J. Cross, AstraZeneca

     Navigating the kinome.
     Michal Vieth, Lilly Res. Labs.

     When simple agonism is not enough: Emerging modalities of GPCR ligands.
     Graeme Milligan, Univ. of Glasgow

     Network pharmacology modeling in systems biology.
     Andrew L. Hopkins, Univ. of Dundee, United Kingdom

     Evaluation and analysis of a dense multifunctional psychiatric drug space.
     Michael W. Wood, AstraZeneca Pharmaceuticals LP

     Summary discussion.
     Alan J. Cross, AstraZeneca

/uploadedImages/Meeting/Annual_Meeting/Sanders_Bush.gif JULIUS AXELROD LECTURE
  San Diego Convention Center, Room 2
  2:00 pm – 3:00 pm

Elaine Sanders-Bush, Vanderbilt Univ. Sch. of Med.
  From farm to pharm: A journey with serotonin.


JULIUS AXELROD SYMPOSIUM: Novel insights into  the regulation of serotonin function
San Diego Convention Center, Room 2
3:00 pm – 5:30 pm
Chair: Elaine Sanders-Bush, Vanderbilt Univ. Sch. of. Med.

     Modulation of serotonin homeostasis by integrin signaling pathways.
     Ana Carneiro, Vanderbilt Univ. Sch. of Med.

     Allosteric regulation of serotonin 5-HT2C receptor function.
     Kathryn A. Cunningham, Univ. of Texas Med. Br., Galveston

     Role of ßarrestins in agonist-directed serotonin 5-HT2A receptor signaling in vivo
     Laura Bohn, Scripps Res. Inst., Jupiter

The behavior of pain
San Diego Convention Center, Room 3
3:00 pm – 5:30 pm
Sponsored by the Divisions for Behavioral Pharmacology; Drug Discovery, Development & Regulatory Affairs; and Neuropharmacology
Chair: Thomas J. Martin, Wake Forest Univ. Hlth Sci.

     Translating pain research from the laboratory to the clinic.
     Jianren Mao, Massachusetts General Hosp.

     The role of drug self-administration as a tool for preclinical pain research.
     Thomas J. Martin, Wake Forest Univ. Hlth Sci.

     Pain-depressed behaviors as novel tools for addressing analgesic efficacy in laboratory animals.
     S. Stevens Negus, Virginia Commonwealth Univ.

     Future directions and challenges in the development of novel therapies for pain.
     Frank Porreca, Univ. of Arizona Coll. of Med.

Role of nuclear receptors in lipid dysregulation and obesity-related diseases
San Diego Convention Center, Room 5A
3:00 pm – 5:30 pm
Sponsored by the Divisions for Drug Metabolism; Integrative Systems, Translational & Clinical Pharmacology; and Toxicology
Chairs: John Chiang, Northeastern Ohio Univ. Col. of  Med. And Hollie Swanson, Univ. of Kentucky Col. of Med.

     Introduction.
     Hollie Swanson, Univ. of Kentucky Col. of Med.

     PXR and CAR as therapeutic targets for obesity type 2 diabetes.
     Wen Xie, Univ. of Pittsburgh Sch. of Pharm.

     Bile acid activated receptors in regulating lipid and glucose metabolism.
     Stefano Fiorucci, Univ. of Perugia, Italy

     Tissue specific functions of the farnesoid X receptor in liver and intestine.
     Grace Guo, Univ. of Kansas Med. Center

     Impact of selective estrogen receptor beta ligands on obesity.
     Ramesh Narayanan, GTx, Inc.

Emerging role of heme oxygenase in cardiovascular and metabolic diseases
San Diego Convention Center, Room 5B
3:00 pm – 5:30 pm
Sponsored by the Divisions for Cardiovascular Pharmacology and Integrative Systems, Translational & Clinical Pharmacology
Chairs: Nader G. Abraham, Univ. of Toledo

     Heme oxygenase induced adiponectin upregulation in epicardial fat ameliorates ischemia-induced cardiac dysfunction.
     Stephen J.Peterson, New York Med. Col.

     Molecular regulation of heme oxygenase.
     Anupam Agarwal, Univ. of Alabama-Burmingham

     EET-agonist regulates Mesenchymal Stem Cells-derived adipocytes through activation of heme oxygenase-1 (HO-1).
     Nader G.Abraham, Univ. of Toledo

     Heme oxygenase and blood pressure regulation.
     David E. Stec, Univ. of Mississippi Med. Ctr.

     Role of heme oxygenase and its metabolites in the regulation of cerebral vascular function.
     Charles Leffler, Univ. of Tennessee Hlth. Sci. Ctr.

Adapting TBL techniques to teach pharmacology to graduate, professional and medical students
San Diego Marriott Marquis & Marina, Marriott Hall, Salon 5
3:00 pm – 5:30 pm
Sponsored by the Division of Pharmacology Education
Chair: R. Senthil Kumar, St Matthew's Univ. Sch. of Med., Grand Cayman Islands

     Revisiting concepts of Team based learning. Addressing concerns.
     R. Senthil Kumar, St Matthew's Univ. Sch. of Med., Grand Cayman Islands

     Exploring the advances in technology to augment outcomes in TBL.
     John Szarek, The Commonwealth Med. Col.

     Use of TBL sessions in an introductory graduate pharmacology courses.
     George Dunaway, Southern Illinois Univ. Sch. of Med.

Back to top

 

Monday, April 23, 2012

Location, location, location:  The role of membrane microdomains in dopamine transporter function and trafficking
San Diego Convention Center, Room 2
9:30 am – 12:00 pm
Sponsored by the Divisions for Neuropharmacology and Molecular Pharmacology
Chairs: Habibeh Khoushbouei, Meharry Med. Col. and Haley Melikian, Univ. of Massachusetts Sch. of Med.

     Relationship between DAT phosphorylation states and lipid raft localization.
     Roxanne Vaughan, Univ. of North Dakota Sch. of Med. and Hlth. Sci.

      Flotilin-1: A critical regulator of dopamine transporter lipid raft localization, PKC-mediated internalization and amphetamine-mediated DA efflux.
      Ai Yamamoto, Columbia Univ. Med. Ctr.

     The role for the neuronal GTPase, rin, in dopamine transporter microdomain localization and trafficking.
     Haley Melikian, Univ. of Massachusetts Sch. of Med.

     Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding.
     Susan Amara, Univ. of Pittsburgh Sch. of Med.

     Membrane microdomain localization and trafficking of dopamine transporter coding variants associated with ADHD.
     Randy Blakely, Vanderbilt Univ. Med. Ctr.

Cognitive enhancement to improve treatment outcome and quality of life associated with neuropathologies
San Diego Convention Center, Room 3
9:30 am – 12:00 pm
Sponsored by the Divisions for Behavioral Pharmacology; Neuropharmacology; and Toxicology
Chairs: Robert Gould, Wake Forest Univ. Sch. of Med. and Michael A. Nader, Wake Forest Univ. Sch. of Med.

     Models of cognition and their predictive validity.
     Robert Gould, Wake Forest Univ. Sch. of Med.

     Cognitive deficits associated with cancer chemotherapy and potential pharmacological treatments.
     Ellen Walker, Temple Univ. Sch. of Pharm.

     Neurobiological, functional, and cognitive deficits associated with cocaine addiction.
     Sam Deadwyler, Wake Forest Univ. Hlth. Sci.

     Cognitive deficits associated with Parkinson's disease: Clinical and pre-clinical perspectives.
     Jay Schneider, Thomas Jefferson Univ., Jeff. Med. Col. 

     Nicotinic acetylcholine receptors as targets for cognitive enhancement.
     Martin Sarter, Univ. of Michigan

Perivascular (p)fat:  Pharmacology, physiology and (P)function
San Diego Convention Center, Room 4
9:30 am – 12:00 pm
Sponsored by the Divisions for Cardiovascular Pharmacology and Integrative Systems, Translational & Clinical Pharmacology
Chairs: Ann Dorrance, Michigan State Univ. and Stephanie Watts, Michigan State Univ.

     Introduction.
     Ann Dorrance, Michigan State Univ.

     Emerging fields of study on the adipose tissue
     Kate J. Claycombe, USDA-ARS, Grand Forks

      Vasodilator signals from perivascular adipose tissue.
     Maik Gollasch, Charite Univ. Medicine, Berlin

     Role of the perivascular renin-angiotensin system in vascular diseases.
     Lisa Cassis, Univ. of Kentucky Col. of Med.

     Indoleamine diooxygenase (IDO) in PVAT: presence and (ph)function.
     Stephanie Watts, Michigan State Univ.

     Modulation of vascular function by perivascular adipose tissue in health and in disease.
     Robert M.K.W. Lee, McMaster Univ., Ontario

     Effects of perivascular adipose tissue (PVAT) on the contractile function of rat resistance arteries.
     Theodora Szasz, Georgia Hlth. Sci. Univ.

The real world of therapeutic drugs: Bench to boardroom, the bedside and beyond
San Diego Convention Center, Room 5A
9:30 am – 12:00 pm
Sponsored by the Divisions for Pharmacology Education and Behavioral Pharmacology
Chair: P.K. Rangachari, McMaster Univ., Ontario  

     Framing interdisciplinary courses: Promises and pitfalls.
     P.K. Rangachari, McMaster Univ., Ontario 

     Tomorrow’s prescribers: How should we train them, assess them and support them?
     Simon Maxwell, Univ. of Edinburgh 

     That’s a great drug, but who’s paying for it - Beyond the do no harm paradigm
     Nicole Yurgin, Amgen, Inc.

     Discussing the benefit & risks of drug therapies: interpreting drug information for healthcare providers and patients.
     Sandra Milligan, Amgen, Inc. 

     Social Pharmacology: a new topic in Pharmacology.
     J.L. Montastruc, Univ. Paul Sabatier, Toulouse 

Drug Discovery, Development and Regulatory Affairs Symposium: Mitochondrial dysfunction in human disease
San Diego Convention Center, Room 5B
9:30 am – 12:00 pm
Chairs: Robert E. Davis, 3-D Pharmaceut. Consultants and Michael Williams, Northwestern Univ.

     Introduction: Mitochondrial dysfunction and human disease.
     Robert K. Naviaux, Univ. of California, San Diego Sch. of Med.

     Mitochondrial dysfunction in neurodegenerative diseases.
     M. Flint Beal, Cornell Univ. Weill Med. Col.

     Mitochondrial bioenergetics and the etiology of diabetes.
     Darell Neufer, East Carolina Univ. Brody Sch. of Med.

     Warburg revisited: Regulation of mitochondrial metabolism by voltage dependent anion channels in cancer cells.
     John J. Lemasters, Med. Univ. of South Carolina

     Therapeutic potential for mitochondrial disease treatment.
     Robert E. Davis, 3-D Pharmaceut. Consultants    

Public Affairs Workshop: FDA's Strategy to Develop and Validate New Anticancer and Cancer Prevention Agents and Pathways
San Diego Convention Center, Room 4
1:00 pm - 2:50 pm
Chair: Kenneth D. Tew, Medical Univ. of South Carolina

    
Pitfalls in oncology development
     Katherine Delorenzo, FDA
   
     Oncology drug development
     Stacy Shord, FDA

     Bridging the gap between drug discovery & clinical trials: non-clinical development of oncology drugs
     Haleh Saber, FDA

/uploadedImages/Meeting/Annual_Meeting/Barrett (PB Dews).jpgP.B. Dews Award Lecture in Behavioral Pharmacology
  San Diego Convention Center, Room 2
  2:00 pm – 3:00 pm

  James E. Barrett
, Drexel Univ. Sch. of Med.
  Drugs of abuse: behavioral determinants of pharmacological plasticity

    
/uploadedImages/Meeting/Annual_Meeting/Sugiyama (Brodie) edit.jpg  B.B. Brodie Award Lecture in Drug Metabolism

  San Diego Convention Center, Room 3
  2:00 pm – 3:00 pm

Yuichi Sugiyama, Univ. of Tokyo
Drug transporters: roles in new drug discovery and development


Behavioral Pharmacology Division Symposium: The behavioral pharmacology of drugs of abuse and drug dependence: A tribute to Steve Holtzman and Bob Schuster
San Diego Convention Center, Room 2
3:00 pm – 5:30 pm
Chairs: Linda Dykstra, Univ. of North Carolina at Chapel Hill and Carol Paronis, Northeastern Univ.

     Lessons learned from two of the best.
     Linda Dykstra, Univ. of North Carolina at Chapel Hill

     Some determinants of drug tolerance and dependence.
     Carol Paronis, Northeastern Univ.

     Use of non-human primate models in intravenous drug self administration in the development of medications for the treatment of drug abuse.
     Steve Goldberg, Johns Hopkins Univ. Bayview Med. Ctr.

     Vive la difference:  Sex differences in the behavioral pharmacology of opioids.
     Rebecca Craft, Washington State Univ.

     Building bridges, solving problems: connecting behavioral pharmacological models of self-administration to treatments.
     Mark Greenwald, Wayne State Univ. Sch. of Med.

Drug Metabolism Division and James Gillette Award and Platform Session
San Diego Convention Center, Room 3
3:00 pm – 5:30 pm

Molecular Pharmacology Division Postdoctoral Award Finalists
San Diego Convention Center, Room 4
3:00 pm – 5:30 pm

     Keynote:Acyl tales of G proteins and PATs
     Maurine E. Linder, Cornell University

Integrative Systems, Translational and Clinical Pharmacology Division Young Investigator Awards Platform Session
San Diego Convention Center, Room 5A
3:00 pm – 5:30 pm

 Pharmacology Education Division Symposium:Strategies for pharmacology in integrated medical school curricula: Best practices for enhancing involvement of our discipline
San Diego Convention Center, Room 5B
3:00 pm – 5:30 pm

     The knowledge objectives in pharmacology: our leverage in the curriculum
     Richard Eisenberg, Univ. of Minnesota

     Creation of a virtual pharmacology course in an organ-based, PBL-intensive medical curriculum
     Kent Vrana, Penn State

     Medical pharmacology in an expanding world
     J.R. Haywood, Michigan State Univ.

     Starting with a blank slate: building the curriculum in a new medical school
     Lynn Crespo, Univ. of South Carolina, Greenville

Back to top

 

Tuesday, April 24, 2012

/uploadedImages/Meeting/Annual_Meeting/Zhang (Abel)-cropped.jpgJ.J. Abel Lecture
  San Diego Convention Center, Room 2
  8:30 am – 9:30 am

Jin Zhang, Johns Hopkins Sch. of Med.
Spatiotemporal regulation of protein kinases in living cells


Membrane rafts in endothelial signaling

San Diego Convention Center, Room 2
9:30 am – 12:00 pm
Sponsored by the Divisions for Cardiovascular Pharmacology and Integrative Systems, Translational & Clinical Pharmacology
Chairs: Irena Levitan, Univ. of Illinois at Chicago and Pin-Lan Li, Virginia Commonwealth Univ., Med. Col. of Virginia

    The role of lipid rafts in endothelial redox signaling.
     Pin-Lan Li, Virginia Commonwealth Univ., Med. Col. of Virginia

     Paradoxical effects of modified low-density lipoproteins on endothelial membrane rafts.
     Irena Levitan, Univ. of Illinois at Chicago

     Role of membrane rafts and caveolae in the sensitivity of endothelial cells to hemodynamic forces.
     Victor Rizzo, Temple Univ. Sch. of Med.

     Membrane rafts in endothelial function of the cerebral circulation.
     Thomas P. Davis, Univ. of Arizona

Toll-like receptors in neuroplasticity and disease
San Diego Convention Center, Room 3
9:30 am – 12:00 pm
Sponsored by the Divisions for Molecular Pharmacology; Neuropharmacology; and Integrative Systems, Translational & Clinical Pharmacology
Chair: Mark Mattson, NIA, NIH

     Developmental reprogramming of TLR signaling.
     Quentin J. Pittman, Univ. of Calgary 

     Roles for TLRs in the regulation of behavior.
     Eitan Okun, Bar Ilan Univ, Israel/NIA, NIH

     Roles for TLRs in Ischemic stroke and Alzheimer's disease.
     Mark Mattson, NIA, NIH

     Mobilizing innate immune attack on brain amyloidosis.
     Thomas Wisniewski, New York Univ. Sch. of Med.

The Nociceptin/orphanin FQ-NOP receptor system:  Neurobiology, pharmacology and therapeutic opportunities
San Diego Convention Center, Room 4
9:30 am – 12:00 pm
Sponsored by the Divisions for Neuropharmacology and Behavioral Pharmacology
Chair: Girolamo Calo, Univ. of Ferrara, Italy

     Milestones in nociceptin/orphanin FQ research.
     Rainer Reinscheid, Univ. of California Irvine

     The Nociceptin/orphanin FQ-NOP receptor system as a target for treating addiction.
     Niall P. Murphy, UCLA

     Nociceptin/orphanin FQ receptors as candidate for innovative antidepressant drugs.
     Elaine Cristina Gavioli, Federal Univ. of Rio Grande do Norte, Brazil

     Therapeutic potential of NOP agonists as analgesics without abuse liability.
     Mei Chuan Ko, Univ. of Michigan Med. Sch.

     NOP receptor ligands in parkinsonism and levodopa-induced dyskinesia.
     Michele Morari, Univ. of Ferrara, Italy

From structure to knockout:  Common themes between CYPs and ABC transporters
San Diego Convention Center, Room 5A
9:30 am – 12:00 pm
Sponsored by the Divisions for Toxicology; Drug Metabolism; and Drug Discovery, Development & Regulatory Affairs; and Neuropharmacology
Chair: Mary Vore, Univ. of Kentucky

     Structure of multidrug resistance transporters.
     Geoffrey Chang, Univ. of California, San Diego

     Structural characteristics of drug metabolizing P450s: Implications for drug development.
     Eric F. Johnson, Scripps Res. Inst.

     Role of ABC transporters in ADME-- Translation from knockout mice to clinics.
     Yuichi Sugiyama, Univ. of Tokyo Sch. of Pharmaceut. Sci.

     Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment.
     Frank Gonzalez, NCI, NIH

Models of affective disorders and pharmacological interventions:  The influence of etiology in treatment approach
San Diego Convention Center, Room 5B
9:30 am – 12:00 pm
Sponsored by the Divisions for Behavioral Pharmacology; Drug Metabolism; and Drug Discovery, Development & Regulatory Affairs; and Neuropharmacology; and Neuropharmacology
Chairs: Michael A. Nader, Wake Forest Univ. Sch. of Med. and Leonard Howell, Emory Univ. Sch. of Med.

     Individual differences in response to treatments.
     Charles O'Brien, Univ. of Pennsylvania Sch. of Med.

     Cross-species tests of potential predictors of responders to antipsychotic treatments.
     Mark Geyer, UCSD

     Convergence of impulsivity and addictive phenotypes: Preclinical evidence for the role of serotonin 5-HT2A and 5-HT2C receptor homeostasis.
     Kathryn Cunningham, Univ. of Texas Med.Branch

     The relationship between gender and psychotic symptoms in drug abusers.
     Richard De La Garza II, Baylor Col. of Med.

     Drug x host x environment interactions in nonhuman primate models of cocaine abuse.
     Michael A. Nader, Wake Forest Univ. Sch. of Med.

Women in Pharmacology Committee Career Round-Table
San Diego Convention Center, Room 12
1:00 pm - 3:00 pm
Do you have questions about your career development? The following speakers will be present to talk to you personally about life in the industry, academia, and other fields:

Representing academia: Martha I. Davila-Garcia (Howard University) and Margarita Dubocovich (University of Buffalo)
Representing industry: Jelveh Lamah (Genoptix Medical Laboratory)
Representing research institutes: Laura Bohn (Scripps Research Institute)
Representing new hires: Richard Wainford (Boston University) and Jun-Xo Li (University of Buffalo)
Representing associations: Christie Carrico (ASPET)

Cardiovascular Pharmacology Division Trainee Showcase
San Diego Convention Center, Room 2
2:30 pm – 4:30 pm

Neuropharmacology Division Postdoctoral Scientist Award Finalists
San Diego Convention Center, Room 3
3:00 pm – 5:30 pm

Regulation of TRP channels
San Diego Convention Center, Room 4
3:00 pm – 5:30 pm
Sponsored by the Divisions for Molecular Pharmacology and Neuropharmacology
Chair: Michael Zhu, Univ. of Texas Hlth Sci. Ctr. at Houston

     Physiological functions of TRP channels as revealed from TRP knockout mice.
     Veit Flockerzi, Univ. of Saarland, Germany

     Functional regulation and physiological roles of TRPM channels.
     Andrea Fleig, Queen's Med. Ctr. And Univ. of Hawai'i at Maoa

     Phosphoinositide regulation of TRP channels.
     Tibor Rohacs, Univ. of Med. and Dent. of New Jersey, New Jersey Med. Sch.

     Function and regulation of intracellularly localized TRPML channels.
     Haoxing Xu, Univ. of Michigan

Toxicology Division Symposium: The utilization of genetically modified mice to determine mechanisms of toxicity
San Diego Convention Center, Room 5A
3:00 pm – 5:30 pm
Chairs: Jack A. Hinson, Univ. of Arkansas for Med. Sci.


     Introduction.
     Jack A. Hinson, Univ. of Arkansas for Med. Sci.

     Role of P450 and nuclear receptor transgenic mice in determining mechanisms of chemical hepatotoxicity.
     Frank J. Gonzalez, NCI, NIH

     Transgenic mouse models for modulating glutathione synthesis.
     Terrance J. Kavanagh, Univ. of Washington

     Signal transduction pathways in the mechanisms of hepatotoxicity.
     Neil Kaplowitz, Univ. of Southern California, Keck Sch. of Med.

     Drug-induced enteropathy - Mechanistic insights from gene knockout models.
     Urs A. Boelsterli, Univ. of Connecticut Sch. of Pharm.

Targeting PI3K for human diseases
San Diego Convention Center, Room 5B
3:00 pm – 5:30 pm
Sponsored by the Divisions for Drug Metabolism; and Drug Discovery, Development & Regulatory Affairs; Toxicology; and Molecular Pharmacology
Chair: Tadimeti S. Rao, Johnson and Johnson, PRD

     PI3K structure, function, regulation in disease & drug targeting.
     David Fruman, Univ. of California, Irvine

     PI3K-gamma: an essential regulator of tumor inflammation and tumor growth
     Judith A. Varner, Univ. of California, San Diego

     Targeting the PI3K pathway for immune-mediated diseases.
     Christian Rommel, Intellikine, Inc.

     PI3K δ and steroid resistance in airway inflammation-mechanisms and opportunities.
     Kazuhiro Ito, Imperial College London

/uploadedImages/Meeting/Annual_Meeting/Cohen (Vanhoutte).jpgPaul Vanhoutte Award Lecture in Cardiovascular Pharmacology
  San Diego Convention Center, Room 2
  4:30 pm – 5:30 pm

Richard A. Cohen, Boston Univ. Sch. of Med.
Nitric oxide in metabolic cardiovascular disease


ASPET Student-Postdoc Mixer
9:00 – 11:30pm at Marriott, Marriott Hall Salon 2

Back to top

 

Wednesday, April 25, 2012

RAY FULLER LECTURE: Fulfilling the promise of molecular medicine in autism spectrum disorders
San Diego Convention Center, Room 2
8:30 am – 9:30 pm
Mark Bear, Howard Hughes Med. Inst.

RAY FULLER SYMPOSIUM: Progress toward autism drug discovery
San Diego Convention Center, Room 2
9:30 am – 12:00 pm
Chair: Mark Bear, Howard Hughes Med. Inst.

     Targeted therapeutics for individuals with autism spectrum disorders.
     Paul Wang, Seaside Therapeutics

     Allosteric modulators of GPCRs as a novel approach for treatment of CNS disorders.
     P. Jeffrey Conn, Vanderbilt Univ. Med. Ctr.
        
     Drug discovery and development for autism and related disorders
     Fabrizio Gasparini, Novaris Institute for Biomedical Research, Switzerland  

Protein-protein interaction (PPI) interfaces as therapeutic targets:  promises and challenges
San Diego Convention Center, Room 3
9:30 am – 12:00 pm
Sponsored by the Divisions for Molecular Pharmacology; and Drug Discovery, Development & Regulatory Affairs; Toxicology
Chairs: Haian Fu, Emory Univ.

     Introduction
     Haian Fu, Emory Univ.

     Targeting PPI interfaces in drug discovery: Key attributes of successful compounds.
     David C. Fry, Hoffmann-La Roche, Inc.

     Fragment-based drug discovery approach for challenging targets: PPI.
     Michelle Arkin, UCSF

     Computational scaffold design approach for the discovery of PPI inhibitors.
     Shaomeng Wang, Univ. of Michigan

      Targeting PPIs to interrogate survival signaling network in cancer.
      Haian Fu, Emory Univ.

NADPH-CYP450 oxidoreductase:  Roles in physiology, pharmacology, and toxicology
San Diego Convention Center, Room 4
9:30 am – 12:00 pm
Sponsored by the Divisions for Drug Metabolism; Toxicology; and Drug Discovery, Development & Regulatory Affairs; Toxicology
Chairs: Todd D. Porter, Univ. of Kentucky Col. of Pharm. and David S. Riddick, Univ. of Toronto

     Introduction.
     David S. Riddick, Univ. of Toronto

     Engineered mouse models harboring null or hypomorphic alleles for NADPH-cytochrome P450 oxidoreductase.
     Xinxin Ding, New York State Department of Health

     Mouse models for deciphering the roles of NADPH-cytochrome P450 oxidoreductase and cytochrome b5 in physiology, drug metabolism and cancer.
     C. Roland Wolf, Univ. of Dundee, Ninewlls Hosp. and Med. Sch., UK

     Replication of the hepatic lipidosis seen in hepatic POR-null mice in a hepatoma cell culture model: A role for FXR?
     Todd D. Porter, Univ. of Kentucky Col. of Pharm.

     Clinical, structural and functional implications of mutations and polymorphisms in human NADPH-cytochrome P450 oxidoreductase.
     Amit V. Pandey, Univ. of Bern, Switzerland

Opioid-induced bowel dysfunction
San Diego Convention Center, Room 5A
9:30 am – 12:00 pm
Sponsored by the Divisions for Integrative Systems, Translational & Clinical Pharmacology; Toxicology; and Neuropharmacology
Chair: Hamid I. Akbarali, Virginia Commonwealth Univ.

     Opiate receptor function in enteric neurons.
     Catia Sternini, UCLA Sch. of Med.

     Peripheral opiate antagonists- current usage in treating OBD.
     Richard Mangano, Adolor Corp.

     Opioid tolerance and bowel dysfunction.
     Hamid I. Akbarali, Virginia Commonwealth Univ.

     Mu opioid receptor biased ligands: Delivering powerful analgesia and minimizing side effects.
     Scott DeWire, Trevana, Inc.

     Narcotic bowel syndrome.
     Doug Drossman, Univ. of North Carolina Sch. of Med.

 Discovery of protein kinase inhibitors for CNS disorders: Opening new avenues for unmet needs

San Diego Convention Center, Room 3
3:00 pm – 5:30 pm
Sponsored by the Divisions for Neuropharmacology; Behavioral Pharmacology; and Molecular Pharmacology
Chairs: Margaret Gnegy, Univ. of Michigan Sch. of Med. and Daniel M. Watterson, Northwestern Univ. Feinberg Sch. of Med.

     Guiding medicinal chemistry with pharmacology in novel small molecule kinase inhibitor discovery: A case study.
     Daniel M. Watterson, Northwestern Univ. Feinberg Sch. of Med.

     Protein kinase inhibitors as therapeutics for Neurodegenerative diseases: cdk5 as a case study
     Marcie Glicksman, Harvard Med. Sch.

     Application of fragment-based lead discovery to identify specific targeted protein kinase inhibitors for CNS disorders.
     Vicki Nienaber, Zenobia Therapeutics, Inc.

     TBA
     Rong Chen, Univ. of Michigan Med. Sch.

Steroid signaling via G protein-coupled receptors
San Diego Convention Center, Room 4
3:00 pm – 5:30 pm
Sponsored by the Divisions for Molecular Pharmacology; Integrative Systems, Translational & Clinical Pharmacology; Neuropharmacology; Toxicology; and Cardiovascular Pharmacology
Chairs: Eric E. Prossnitz, Univ. of New Mexico

     What have selective ligands told us about GPER function?
     Eric E. Prossnitz, Univ. of New Mexico

     G protein-coupled estrogen receptor-1, GPER-1: its mechanism of desensitization and role in cancer.
     Edward Filardo, Brown Univ. Sch. of Med.

     Actions of GPER on the vasculature.
     Matthias Barton, Univ. of Zurich

     GPER: a GPCR mediator of estrogen actions in the brain.
     Diane Lebesgue, Albert Einstein Col. of Med.

Clinical pipeline of marine pharmaceuticals:  The odyssey continues

San Diego Convention Center, Room 5A
3:00 pm – 5:30 pm
Sponsored by the Division for Drug Discovery, Development & Regulatory Affairs; Toxicology
Chairs: Keith B.Glaser, Abbott Laboratories  and Alejandro M.S. Mayer, Midwestern Univ.

     Overview of the current marine clinical pharmaceutical pipeline.
     Keith B.Glaser, Abbott Laboratories 

     Discovery of Eribulin mesylate (Halaven®):  From marine natural product to FDA approved drug.
     Melvin Yu, EISAI Inc.

     Discovery and development of ADCETRIS: an approved antibody drug conjugate for cancer therapy.
     Peter Senter, Seattle Genetics

     Discovery and development from marina microbiology of the anticancer compounds plinabulin (NPI-2358) and marizomib (NPI-0052).
     G. Kenneth Lloyd, Nereus Pharmaceuticals, Inc.

     Overview of the current preclinical marine pharmacology pipeline.
     Alejandro M.S. Mayer, Midwestern Univ.

Applications of biomaterials and drug delivery systems for enhancing tissue engineering and regeneration
San Diego Convention Center, Room 5B
3:00 pm – 5:30 pm
Sponsored by the Division for Integrative Systems, Translational & Clinical Pharmacology
Chairs: Karl-Erik Andersson, Wake Forest Univ. Hlth Sci. and George J. Christ, Wake Forest Univ. Hlth. Sci 

     Biomaterials and biofunctional nanoparticles for tissue engineering and other biomedical applications.
     Jeff Hubbel, Ecole Polytechnique Federale de Lausanne Sch. of Life Sci., Switzerland

     Injectable hydrogels for delivery of therapeutic agents for treatment of peripheral and central nervous system injury.
     Molly Shoichet, Univ. of Toronto

     Polymeric materials and conjugates for systemic drug and gene delivery.
     Patrick Statyon, Univ. of Washington

     Hydrogel drug delivery systems for musculoskeletal repair.
     Johnna Temenoff, Georgia Tech. Inst. 

     Delivery of nucleic acids to regulate the local environment in tissue engineering applications.
     Justin M. Saul, Wake Forest Univ. Hlth. Sci.

ASPET Closing Reception
San Diego Marriott Marquis & Marina, Poolside Terrace
6:00 pm - 8:00 pm

Back to top

Explore Pharmacology
ASPET Annual Meeting 2015 
Apply for Membership
PharmTalk Blog